Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab in Advanced Malignancies
NCT02404441Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 14
01
Overview
A Phase 2 trial of spartalizumab in melanoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), anaplastic thyroid cancer (ATC), solid tumor, sponsored by Novartis. Started Apr 2015; status: completed.
02
Drugs
spartalizumab
03
Conditions
melanomanon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)anaplastic thyroid cancer (ATC)solid tumor
Beyond the preview
Go deeper on NCT02404441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404441.